{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:49:27Z","timestamp":1791395367733,"version":"4.3.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019387","name":"Saitama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019387","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40261-026-01549-9","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:35:56Z","timestamp":1775842556000},"page":"619-630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Willingness to Pay for Treatment Attributes in Diffuse Large B-Cell Lymphoma: A Discrete Choice Experiment in Japan"],"prefix":"10.1007","volume":"46","author":[{"given":"Yasuyuki","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Bolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LoPresti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Arguissain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-2793","authenticated-orcid":false,"given":"J\u00f6rg","family":"Mahlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"20","key":"1549_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"5","key":"1549_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141(5):467\u201380.","journal-title":"Blood"},{"issue":"5","key":"1549_CR3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/ejh.14166","volume":"112","author":"N Yamauchi","year":"2024","unstructured":"Yamauchi N, Maruyama D. Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma. Eur J Haematol. 2024;112(5):662\u201377.","journal-title":"Eur J Haematol"},{"issue":"5","key":"1549_CR4","doi-asserted-by":"publisher","first-page":"339.e1","DOI":"10.1016\/j.jtct.2025.02.013","volume":"31","author":"C Yamamoto","year":"2025","unstructured":"Yamamoto C, Honda S, Tominaga R, Yokoyama D, Furuki S, Noguchi A, et al. Impact of real-world clinical factors on an analysis of the cost-effectiveness of \u201cimmediate CAR-T\u201d versus \u201clate CAR-T\u201d as second-line treatment for DLBCL patients. Transplant Cell Ther. 2025;31(5):339.e1-339.e15.","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"1549_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"7","key":"1549_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14737167.2023.2223984","volume":"23","author":"A Takami","year":"2023","unstructured":"Takami A, Kato M, Deguchi H, Igarashi A. Value elements and methods of value-based pricing for drugs in Japan: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2023;23(7):749\u201359.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1549_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2023.1205016","volume":"14","author":"Y Itani","year":"2023","unstructured":"Itani Y, Obama K, Fujimori M, Saito J, Uchitomi Y. Cancer treatment-related financial toxicity in Japan: a scoping review. Front Psychol. 2023;14:1205016.","journal-title":"Front Psychol"},{"issue":"8","key":"1549_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. Pharmacoeconomics. 2008;26(8):661\u201377.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1549_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40271-021-00520-4","volume":"14","author":"H Collacott","year":"2021","unstructured":"Collacott H, Hall C, Lloyd A, Tervonen T. A systematic review of discrete choice experiments in oncology: 2008\u20132020. Patient. 2021;14(6):775\u201390.","journal-title":"Patient"},{"issue":"25","key":"1549_CR10","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.2217\/fon-2022-0421","volume":"18","author":"K Birch","year":"2022","unstructured":"Birch K, Snider JT, Chiu K, et al. Patient preferences for treatment in relapsed\/refractory diffuse large B-cell lymphoma: a discrete choice experiment. Future Oncol. 2022;18(25):2791\u2013804.","journal-title":"Future Oncol"},{"issue":"34","key":"1549_CR11","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.2217\/fon-2021-0160","volume":"17","author":"M Boeri","year":"2021","unstructured":"Boeri M, Saure D, Vandendriessche B, et al. Physician preferences in CAR T-cell therapy for relapsed\/refractory DLBCL: results from a discrete choice experiment. Future Oncol. 2021;17(34):4697\u2013707.","journal-title":"Future Oncol"},{"issue":"2","key":"1549_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clinthera.2017.12.012","volume":"40","author":"T Bolt","year":"2018","unstructured":"Bolt T, Mahlich J, Nakamura Y, Nakayama M. Hematologists\u2019 preferences for first-line therapy characteristics for multiple myeloma in Japan: attribute rating and discrete choice experiment. Clin Ther. 2018;40(2):296-308.e2.","journal-title":"Clin Ther"},{"issue":"4","key":"1549_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"issue":"4","key":"1549_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300\u201315.","journal-title":"Value Health"},{"key":"1549_CR15","unstructured":"Ministry of Health, Labour and Welfare. Statistics of physicians, dentists and pharmacists [Internet]. Tokyo 2020. [cited 2024 Mar 27]. Available from: https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/ishi\/20\/index.html."},{"key":"1549_CR16","unstructured":"Tesler H. Nutzenmessung im Gesundheitswesen: Die Methode der Discrete-Choice-Experimente. Z\u00fcrich; 2002."},{"issue":"4","key":"1549_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1055\/s-0032-1330500","volume":"18","author":"A M\u00fchlbacher","year":"2013","unstructured":"M\u00fchlbacher A, Bethge S, Tockhorn A. Pr\u00e4ferenzmessung im Gesundheitswesen: Grundlagen von Discrete-Choice-Experimenten. Gesundheitsokonomie Qualitatsmanagement. 2013;18(4):159\u201372.","journal-title":"Gesundheitsokonomie Qualitatsmanagement"},{"issue":"1","key":"1549_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348.","journal-title":"Ann Oncol"},{"issue":"7","key":"1549_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00432-025-06249-z","volume":"151","author":"JK Schleifenbaum","year":"2025","unstructured":"Schleifenbaum JK, Heger JM, Jost J, et al. Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2025;151(7):203.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16","key":"1549_CR20","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"issue":"9(9)","key":"1549_CR21","volume":"13","author":"M Ernst","year":"2021","unstructured":"Ernst M, Oeser A, Burcu B, et al. Chimeric antigen receptor (CAR) T\u2010cell therapy for people with relapsed or refractory diffuse large B\u2010cell lymphoma. Cochrane Database Syst Rev. 2021;13(9(9)):CD013365.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1549_CR22","doi-asserted-by":"publisher","first-page":"506.e1","DOI":"10.1016\/j.jtct.2021.03.005","volume":"27","author":"S Wakase","year":"2021","unstructured":"Wakase S, Teshima T, Zhang J, et al. Cost effectiveness analysis of Tisagenlecleucel for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma in Japan. Transplant Cell Ther. 2021;27(6):506.e1-506.e10.","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"1549_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/002224379303000303","volume":"30","author":"J Swait","year":"1993","unstructured":"Swait J, Louviere J. The role of the scale parameter in the estimation and comparison of multinomial logit models. J Mark Res. 1993;30(3):305\u201314.","journal-title":"J Mark Res"},{"key":"1549_CR24","doi-asserted-by":"publisher","unstructured":"Arai Y, Bolt T, Onishi H, et al. Risk attitudes and value of hope: survey results from Japanese hematologists and oncologists treating patients with diff uselarge B-cell lymphoma. Sci Rep. 2026. https:\/\/doi.org\/10.1038\/s41598-026-44232-x","DOI":"10.1038\/s41598-026-44232-x"},{"issue":"2","key":"1549_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148\u201357.","journal-title":"N Engl J Med"},{"issue":"14","key":"1549_CR26","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675\u201384.","journal-title":"Blood"},{"issue":"1","key":"1549_CR27","first-page":"10","volume":"7","author":"WY Hwang","year":"2023","unstructured":"Hwang WY, Takahashi S, Choi B, Huang H, Kawamata S, Ng SC, et al. Challenges in global access to CAR-T cells: an Asian perspective. Blood Cell Ther. 2023;7(1):10\u20133.","journal-title":"Blood Cell Ther"},{"issue":"11","key":"1549_CR28","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","volume":"9","author":"FL Locke","year":"2025","unstructured":"Locke FL, Siddiqi T, Jacobson CA, Nikiforow S, Ahmed S, Miklos DB, et al. Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel. Blood Adv. 2025;9(11):2663\u201376.","journal-title":"Blood Adv"},{"issue":"9","key":"1549_CR29","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"MJ Dickinson","year":"2023","unstructured":"Dickinson MJ, Barba P, J\u00e4ger U, Shah NN, Blaise D, Briones J, et al. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov. 2023;13(9):1982\u201397.","journal-title":"Cancer Discov"},{"issue":"1","key":"1549_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"13","key":"1549_CR31","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1182\/bloodadvances.2023012240","volume":"8","author":"S Vadgama","year":"2024","unstructured":"Vadgama S, Pasquini M, Maziarz R, et al. \u201cDon\u2019t keep me waiting\u201d: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes. Blood Adv. 2024;8(13):3519\u201327.","journal-title":"Blood Adv"},{"issue":"8","key":"1549_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237509","volume":"15","author":"S Tsutsu\u00e9","year":"2020","unstructured":"Tsutsu\u00e9 S, Tobinai K, Yi J, Crawford B. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma. PLoS ONE. 2020;15(8):e0237509.","journal-title":"PLoS ONE"},{"issue":"1","key":"1549_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40487-022-00211-6","volume":"11","author":"P Borchmann","year":"2023","unstructured":"Borchmann P, Heger JM, Mahlich J, et al. Costs of German patients with diffuse large B-cell lymphoma: a retrospective health claims data analysis. Oncol Ther. 2023;11(1):65\u201381.","journal-title":"Oncol Ther."},{"key":"1549_CR34","unstructured":"OECD. Length of hospital stay. Available: https:\/\/www.oecd.org\/en\/data\/indicators\/length-of-hospital-stay.html?oecdcontrol-b84ba0ecd2-var3=2019&oecdcontrol-0ad85c6bab-var1=AUS%7CDEU%7CJPN%7CNLD%7CNZL%7CNOR%7CPOL%7CPRT%7CSVK%7CSVN%7CESP%7CSWE%7CCHE%7CTUR%7CGBR%7CUSA. Accessed 30 Dec 2025"},{"issue":"2-3","key":"1549_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/0951484813512287","volume":"26","author":"J Tiessen","year":"2013","unstructured":"Tiessen J, Kambara H, Sakai T, Kato K, Yamauchi K, McMillan C. What causes international variations in length of stay: a comparative analysis for two inpatient conditions in Japanese and Canadian hospitals. Health Serv Manag Res. 2013;26(2\u20133):86\u201394.","journal-title":"Health Serv Manag Res"},{"key":"1549_CR36","volume-title":"Culture\u2019s consequences: comparing values, behaviors, institutions, and organizations across nations","author":"G Hofstede","year":"2001","unstructured":"Hofstede G. Culture\u2019s consequences: comparing values, behaviors, institutions, and organizations across nations. Thousand Oaks: Sage Publications; 2001."},{"key":"1549_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12962-018-0103-1","volume":"16","author":"J Mahlich","year":"2018","unstructured":"Mahlich J, Dilokthornsakul P, Sruamsiri R, Chaiyakunapruk N. Cultural beliefs, utility values, and health technology assessment. Cost Eff Resour Alloc. 2018;16:19.","journal-title":"Cost Eff Resour Alloc"},{"issue":"23","key":"1549_CR38","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1182\/bloodadvances.2024013254","volume":"8","author":"Y Linhares","year":"2024","unstructured":"Linhares Y, Freytes CO, Cherry M, Bachier C, Maris M, Hoda D, et al. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R\/R LBCL. Blood Adv. 2024;8(23):6114\u201326.","journal-title":"Blood Adv"},{"issue":"16","key":"1549_CR39","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1182\/bloodadvances.2024013239","volume":"8","author":"F Furqan","year":"2024","unstructured":"Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, et al. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024;8(16):4320\u20139.","journal-title":"Blood Adv"},{"issue":"24","key":"1549_CR40","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.3390\/cancers15245746","volume":"15","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Liu YH, Ranjan S, Bhandari H, Potluri R, McFarland L, et al. The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: a systematic literature review. Cancers. 2023;15(24):5746.","journal-title":"Cancers"},{"issue":"19","key":"1549_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70177","volume":"13","author":"C Thomas","year":"2024","unstructured":"Thomas C, Marsh K, Trapali M, Krucien N, Worth G, Cockrum P, et al. Preferences of patients and physicians in the United States for relapsed\/refractory follicular lymphoma treatments. Cancer Med. 2024;13(19):e70177.","journal-title":"Cancer Med"},{"key":"1549_CR42","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/PPA.S140226","volume":"11","author":"FX Liu","year":"2017","unstructured":"Liu FX, Witt EA, Ebbinghaus S, DiBonaventura BG, Shinde R, Basurto E, et al. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. Patient Prefer Adher. 2017;11:1389\u201399.","journal-title":"Patient Prefer Adher"},{"key":"1549_CR43","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.2147\/PPA.S248295","volume":"14","author":"B Hauber","year":"2020","unstructured":"Hauber B, Penrod JR, Gebben D, Musallam L. The value of hope: patients\u2019 and physicians\u2019 preferences for survival in advanced non-small cell lung cancer. Patient Prefer Adher. 2020;14:2093\u2013104.","journal-title":"Patient Prefer Adher"},{"issue":"1","key":"1549_CR44","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-023-11598-4","volume":"23","author":"M Zhang","year":"2023","unstructured":"Zhang M, He X, Wu J, Xie F. Differences between physician and patient preferences for cancer treatments: a systematic review. BMC Cancer. 2023;23(1):1126.","journal-title":"BMC Cancer"},{"key":"1549_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.773366","volume":"11","author":"O Fern\u00e1ndez","year":"2022","unstructured":"Fern\u00e1ndez O, L\u00e1zaro-Quintela M, Crespo G, Soto de Prado D, Pinto \u00c1, Basterretxea L, et al. Preferences for renal cell carcinoma pharmacological treatment: a discrete choice experiment in patients and oncologists. Front Oncol. 2022;11:773366.","journal-title":"Front Oncol"},{"issue":"6","key":"1549_CR46","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jval.2021.10.015","volume":"25","author":"S Vadgama","year":"2022","unstructured":"Vadgama S, Mann J, Bashir Z, et al. Predicting survival for chimeric antigen receptor T-cell therapy: a validation of survival models using follow-up data from ZUMA-1. Value Health. 2022;25(6):1010\u20137.","journal-title":"Value Health."},{"issue":"1","key":"1549_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1017\/S0266462317000174","volume":"33","author":"J Mahlich","year":"2017","unstructured":"Mahlich J, Kamae I, Rossi B. A new health technology assessment system for Japan? Simulating the potential impact on the price of simeprevir. Int J Technol Assess Health Care. 2017;33(1):121\u20137.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"1549_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/13696998.2020.1716775","volume":"23","author":"I Kamae","year":"2020","unstructured":"Kamae I, Thwaites R, Hamada A, Fernandez J. Health technology assessment in Japan: a work in progress. J Med Econ. 2020;23(4):317\u201322.","journal-title":"J Med Econ"},{"issue":"5","key":"1549_CR49","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2016.02.020","volume":"19","author":"L Vallejo-Torres","year":"2016","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Castilla I, et al. On the estimation of the cost-effectiveness threshold: why, what, how? Value Health. 2016;19(5):558\u201366.","journal-title":"Value Health"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01549-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01549-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01549-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:02:41Z","timestamp":1779811361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01549-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01549-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VA and JM are employees of Miltenyi Biomedicine. HO and ML are employees of INTAGE Healthcare, a contract research company that received funding from Miltenyi Biomedicine to conduct the study in line with the study protocol. All other authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All individual respondent data are anonymized in the research database to comply with Japanese data protection regulations. Approval from an institutional review board in Japan was obtained prior to conducting the survey: Toukeikai Kitamachi Clinic Ethics Review Board (IRB no. KXJ09854). The study was performed in accordance with the standards of ethics outlined in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all participants prior to participation in the survey. Consent was collected electronically at the beginning of the online questionnaire administered by INTAGE Healthcare Inc. with a PLAMED Inc. panel.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The discrete choice experiment design was generated using Ngene software, and the statistical analyses were conducted using Stata. The analysis code is available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article. All authors read and approved the final version and agree to be accountable for the work. YA, TB, HO, ML, and JM designed the study. VA and JM drafted the manuscript; TB did the statistical analysis. YA, TB, HO, and ML reviewed and revised the manuscript for important intellectual content.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}